Recipharm Biologics and Cobra Biomanufacturing plc combine.

23-Feb-2010 - United Kingdom

Recipharm AB announced that following the successful acquisition of Cobra Biomanufacturing plc, it has now combined it with the existing biologics activities located in Sweden. The integrated business will be known as RecipharmCobra Biologics and will operate as Recipharm’s specialist biologics division.

The combination of both companies capabilities creates a comprehensive biological service offering, encompassing cell line development, analytical and process development and GMP production of recombinant proteins, DNA, viruses and cell products for Phase I, II and III clinical trials. This, together with fill-finish and formulation capabilities, provides customers with a true one stop shop concept for their biologics outsourcing needs.

Simon Saxby, former CEO of Cobra Biomanufacturing, will head up RecipharmCobra Biologics in the newly formed position of Vice President, Biologics. With the integration complete, RecipharmCobra Biologics will have cGMP approved production facilities in Keele and Oxford, UK and Södertälje, Sweden.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances